Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EnimmuneROCO:6564 -2.10%58 Days Inventory is 214.32 as of Dec. 2025, which is 6% above its 10-year median of 202.89. GuruFocus rates ROCO:6564 with a GF Score™ of 58/100 and a GF Value™ of NT$21.10 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 638 Biotechnology companies, Enimmune ranks worse than 62.23% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Enimmune's Average Total Inventories for the
six
months ended in Dec. 2025 was NT$30.05 Mil. Enimmune's Cost of Goods Sold for the
six
months ended in Dec. 2025 was NT$25.59 Mil.
Hence, Enimmune's Days Inventory for the
six
months ended in Dec. 2025 was 214.32.
The historical rank and industry rank for Enimmune's Days Inventory or its related term are showing as below:
ROCO:6564'
s Days Inventory Range Over the Past 10 Years
Min: 6.14 Med: 202.89 Max: 714.03
Current: 249.63
During the past 10 years, Enimmune's highest Days Inventory was 714.03. The lowest was 6.14. And the median was 202.89.
ROCO:6564's Days Inventory is ranked worse than 62.23% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs ROCO:6564: 249.63
Enimmune's Days Inventory
declined
from Dec. 2024 (222.75) to Dec. 2025 (214.32).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Enimmune's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.85.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Enimmune's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 1.18.
Enimmune (ROCO:6564) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Enimmune's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Enimmune's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Enimmune Days Inventory Related Terms
Enimmune Days Inventory Historical Data
* Premium members only.
The historical data trend for Enimmune's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6564 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Enimmune's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enimmune Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enimmune's Days Inventory distribution charts can be found below:
* The bar in red indicates where Enimmune's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enimmune (ROCO:6564) has a Days Inventory of 214.32 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Enimmune and its competitors. This is near median its historical median of 202.89. Over the past decade, Enimmune's Days Inventory has ranged from 6.14 to 714.03. According to the industry distribution chart, Enimmune ranks #397 out of 638 companies in the Biotechnology industry, placing it in the top 62.2%.
Is Enimmune's Days Inventory too high?
Enimmune's current Days Inventory of 214.32 is near median its 10-year median of 202.89. Over the past 10 years, this metric has ranged from a low of 6.14 to a high of 714.03. The Biotechnology industry median Days Inventory is 183.20. Enimmune's value of 214.32 is 17% above this industry median. Based on the distribution chart, Enimmune ranks #397 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Enimmune has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enimmune's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Enimmune ranks #397 out of 638 companies for Days Inventory. This places Enimmune in the lower half of its industry. The industry median Days Inventory is 183.20. Enimmune's value of 214.32 is 17% above this benchmark. Historically, Enimmune's own Days Inventory has ranged from 6.14 to 714.03 over the past decade. While the company's 10-year median is 202.89 vs. the industry median of 183.20, Enimmune has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enimmune's current Days Inventory of 214.32 is 17% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Enimmune and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enimmune's current Days Inventory is 214.32, which is near median its own 10-year median of 202.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enimmune stock overvalued right now?
Based on GuruFocus' analysis, Enimmune (ROCO:6564) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$21.10, compared to a current price of NT$16.30 — trading 22.7% below its estimated fair value. The current Days Inventory is 214.32, which is near median its 10-year median of 202.89 and 17% above the Biotechnology industry median of 183.20. Enimmune's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Enimmune (ROCO:6564), the current Days Inventory is 214.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enimmune (ROCO:6564) Overvalued in 2026?
Based on GuruFocus' analysis, Enimmune stock appears to be undervalued.
The current stock price of NT$16.30 is trading 22.7% below its estimated GF Value™ of NT$21.10.
GuruFocus considers Enimmune to be Modestly Undervalued.
Key valuation signals for ROCO:6564:
Days Inventory: 214.32 (near median its 10-year median of 202.89)
GF Value™: NT$21.10 vs. price of NT$16.30 (22.7% below fair value)
Industry Position: 17% above the Biotechnology median (#397 of 638)
No single metric tells the full story. See the ROCO:6564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enimmune Corp is primarily engaged in the research and development and trading of vaccines, testing reagents and biotechnology services, etc., as well as trading of related western medicines.
58GF Score
Get the complete analysis for ROCO:6564
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6564 has been successfully added to your 
